This HTML5 document contains 131 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00263/identifier/chemspider/
n7http://linked.opendata.cz/resource/AHFS/
n10http://linked.opendata.cz/resource/drugbank/company/
n13http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00263/identifier/chebi/
n24http://linked.opendata.cz/resource/drugbank/mixture/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00263/identifier/wikipedia/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00263/identifier/pharmgkb/
n26http://bio2rdf.org/drugbank:
n20http://linked.opendata.cz/resource/drugbank/drug/DB00263/identifier/bindingdb/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00263/identifier/kegg-compound/
admshttp://www.w3.org/ns/adms#
n28http://linked.opendata.cz/resource/drugbank/drug/DB00263/identifier/pubchem-compound/
n9http://www.drugs.com/mtm/
n27http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n22http://linked.opendata.cz/resource/drugbank/drug/DB00263/identifier/kegg-drug/
n29http://linked.opendata.cz/resource/drugbank/drug/DB00263/identifier/pubchem-substance/
n11http://linked.opendata.cz/resource/drugbank/medicinal-product/
n12http://linked.opendata.cz/ontology/mesh/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00263/identifier/drugbank/
owlhttp://www.w3.org/2002/07/owl#
n6http://linked.opendata.cz/ontology/drugbank/
n14http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n30http://linked.opendata.cz/resource/drugbank/drug/DB00263/identifier/national-drug-code-directory/
n5http://linked.opendata.cz/resource/atc/
n4http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00263
rdf:type
n6:Drug
n6:description
A short-acting sulfonamide antibacterial with activity against a wide range of gram- negative and gram-positive organisms. [PubChem]
n6:group
approved
n6:indication
For the treatment of severe, repeated, or long-lasting urinary tract infections, meningococcal meningitis, acute otitis media, trachoma, inclusion conjunctivitis, nocardiosis, chancroid, toxoplasmosis, malaria and other bacterial infections.
n6:manufacturer
n10:271B424B-363D-11E5-9242-09173F13E4C5 n10:271B424C-363D-11E5-9242-09173F13E4C5 n10:271B424A-363D-11E5-9242-09173F13E4C5 n10:271B425D-363D-11E5-9242-09173F13E4C5 n10:271B424F-363D-11E5-9242-09173F13E4C5 n10:271B4250-363D-11E5-9242-09173F13E4C5 n10:271B424D-363D-11E5-9242-09173F13E4C5 n10:271B424E-363D-11E5-9242-09173F13E4C5 n10:271B4253-363D-11E5-9242-09173F13E4C5 n10:271B4254-363D-11E5-9242-09173F13E4C5 n10:271B4251-363D-11E5-9242-09173F13E4C5 n10:271B4252-363D-11E5-9242-09173F13E4C5 n10:271B4257-363D-11E5-9242-09173F13E4C5 n10:271B4258-363D-11E5-9242-09173F13E4C5 n10:271B4255-363D-11E5-9242-09173F13E4C5 n10:271B4256-363D-11E5-9242-09173F13E4C5 n10:271B425B-363D-11E5-9242-09173F13E4C5 n10:271B425C-363D-11E5-9242-09173F13E4C5 n10:271B4259-363D-11E5-9242-09173F13E4C5 n10:271B425A-363D-11E5-9242-09173F13E4C5
owl:sameAs
n26:DB00263 n27:DB00263
dcterms:title
Sulfisoxazole
adms:identifier
n16:102484 n17:5151 n18:PA164748964 n19:Sulfisoxazole n20:50034452 n21:C07318 n22:D00450 n23:DB00263 n28:5344 n29:46505342 n30:0004-1003-28
n6:mechanismOfAction
Sulfisoxazole is a competitive inhibitor of the enzyme dihydropteroate synthetase. It inhibits bacterial synthesis of dihydrofolic acid by preventing the condensation of the pteridine with para-aminobenzoic acid (PABA), a substrate of the enzyme dihydropteroate synthetase. The inhibited reaction is necessary in these organisms for the synthesis of folic acid.
n6:packager
n10:271B4249-363D-11E5-9242-09173F13E4C5 n10:271B4247-363D-11E5-9242-09173F13E4C5 n10:271B4248-363D-11E5-9242-09173F13E4C5 n10:271B4245-363D-11E5-9242-09173F13E4C5 n10:271B4246-363D-11E5-9242-09173F13E4C5 n10:271B4243-363D-11E5-9242-09173F13E4C5 n10:271B4244-363D-11E5-9242-09173F13E4C5 n10:271B4241-363D-11E5-9242-09173F13E4C5 n10:271B4242-363D-11E5-9242-09173F13E4C5 n10:271B423F-363D-11E5-9242-09173F13E4C5 n10:271B4240-363D-11E5-9242-09173F13E4C5 n10:271B423E-363D-11E5-9242-09173F13E4C5
n6:routeOfElimination
The mean urinary excretion recovery following oral administration of sulfisoxazole is 97% within 48 hours, of which 52% is intact drug, with the remaining as the N4-acetylated metabolite. It is excreted in human milk.
n6:synonym
5-(P-Aminobenzenesulphonamido)-3,4-dimethylisoxazole 5-(P-Aminobenzenesulfonamido)-3,4-dimethylisoxazole N'-(3,4)dimethylisoxazol-5-yl-sulphanilamide Sulphafurazole 3,4-Dimethylisoxazole-5-sulfanilamide Sulfisoxazol Sulfaisoxazole 3,4-Dimethyl-5-sulphonamidoisoxazole Sulfafurazole Sulfadimethylisoxazole Sulfisoxasole Sulfafurazol Sulfasoxazole Sulphisoxazol Sulphadimethylisoxazole N(1)-(3,4-Dimethyl-5-isoxazolyl)sulfanilamide Sulphaisoxazole Sulfafurazolum 4-Amino-N-(3,4-dimethyl-5-isoxazolyl)benzenesulphonamide 3,4-Dimethylisoxazole-5-sulphanilamide 3,4-Dimethyl-5-sulfanilamidoisoxazole N(1)-(3,4-Dimethyl-5-isoxazolyl)sulphanilamide Sulphofurazole Sulfofurazole 4-Amino-N-(3,4-dimethyl-5-isoxazolyl)benzenesulfonamide 5-Sulphanilamido-3,4-dimethyl-isoxazole 5-(4-Aminophenylsulfonamido)-3,4-dimethylisoxazole 5-Sulfanilamido-3,4-dimethylisoxazole 3,4-Dimethyl-5-sulphanilamidoisoxazole Sulphafurazol Sulfisonazole 3,4-Dimethyl-5-sulfonamidoisoxazole
n6:toxicity
LD<sub>50</sub>=6800 mg/kg (Orally in mice)
n4:hasAHFSCode
n7:08-12-20
n6:mixture
n24:271B423C-363D-11E5-9242-09173F13E4C5 n24:271B423D-363D-11E5-9242-09173F13E4C5
n6:salt
n12:hasConcept
n13:M0020779
foaf:page
n9:sulfisoxazole-ophthalmic.html
n6:IUPAC-Name
n14:271B4266-363D-11E5-9242-09173F13E4C5
n6:InChI
n14:271B426C-363D-11E5-9242-09173F13E4C5
n6:Molecular-Formula
n14:271B426B-363D-11E5-9242-09173F13E4C5
n6:Molecular-Weight
n14:271B4268-363D-11E5-9242-09173F13E4C5
n6:Monoisotopic-Weight
n14:271B4269-363D-11E5-9242-09173F13E4C5
n6:SMILES
n14:271B426A-363D-11E5-9242-09173F13E4C5
n6:Water-Solubility
n14:271B427C-363D-11E5-9242-09173F13E4C5 n14:271B4264-363D-11E5-9242-09173F13E4C5
n6:logP
n14:271B427E-363D-11E5-9242-09173F13E4C5 n14:271B4262-363D-11E5-9242-09173F13E4C5 n14:271B4265-363D-11E5-9242-09173F13E4C5
n6:logS
n14:271B427F-363D-11E5-9242-09173F13E4C5 n14:271B4263-363D-11E5-9242-09173F13E4C5
n6:pKa
n14:271B4280-363D-11E5-9242-09173F13E4C5
n4:hasATCCode
n5:J01EB05 n5:S01AB02
n6:H-Bond-Acceptor-Count
n14:271B4272-363D-11E5-9242-09173F13E4C5
n6:H-Bond-Donor-Count
n14:271B4273-363D-11E5-9242-09173F13E4C5
n6:InChIKey
n14:271B426D-363D-11E5-9242-09173F13E4C5
n6:Polar-Surface-Area--PSA-
n14:271B426E-363D-11E5-9242-09173F13E4C5
n6:Polarizability
n14:271B4270-363D-11E5-9242-09173F13E4C5
n6:Refractivity
n14:271B426F-363D-11E5-9242-09173F13E4C5
n6:Rotatable-Bond-Count
n14:271B4271-363D-11E5-9242-09173F13E4C5
n6:affectedOrganism
Enteric bacteria and other eubacteria
n6:casRegistryNumber
127-69-5
n6:category
n6:containedIn
n11:271B4261-363D-11E5-9242-09173F13E4C5 n11:271B425F-363D-11E5-9242-09173F13E4C5 n11:271B4260-363D-11E5-9242-09173F13E4C5 n11:271B425E-363D-11E5-9242-09173F13E4C5
n6:Bioavailability
n14:271B4278-363D-11E5-9242-09173F13E4C5
n6:Ghose-Filter
n14:271B427A-363D-11E5-9242-09173F13E4C5
n6:MDDR-Like-Rule
n14:271B427B-363D-11E5-9242-09173F13E4C5
n6:Melting-Point
n14:271B427D-363D-11E5-9242-09173F13E4C5
n6:Number-of-Rings
n14:271B4277-363D-11E5-9242-09173F13E4C5
n6:Physiological-Charge
n14:271B4276-363D-11E5-9242-09173F13E4C5
n6:Rule-of-Five
n14:271B4279-363D-11E5-9242-09173F13E4C5
n6:Traditional-IUPAC-Name
n14:271B4267-363D-11E5-9242-09173F13E4C5
n6:pKa--strongest-acidic-
n14:271B4274-363D-11E5-9242-09173F13E4C5
n6:pKa--strongest-basic-
n14:271B4275-363D-11E5-9242-09173F13E4C5